REVIEW   

Giornale Italiano di Dermatologia e Venereologia 2019 October;154(5):539-49

DOI: 10.23736/S0392-0488.19.06375-2

Copyright © 2019 EDIZIONI MINERVA MEDICA

language: English

Management of autoimmune blistering diseases in pregnancy and the neonate

Rebecca L. KRAIN ^{1, 2}, Kristen L. CHEN ^{1, 2}, Victoria P. WERTH ^{1, 2} ✉

¹ Department of Dermatology, Corporal Michael J. Crescenz VAMC, Philadelphia, PA, USA; ² Department of Dermatology, University of Pennsylvania, Philadelphia, PA, USA

The management of autoimmune blistering diseases (AIBD) is therapeutically challenging, particularly in patients who plan to conceive, or are pregnant or breastfeeding. Not only is a patient’s immune system altered by pregnancy-associated hormonal changes, but several medications used for AIBD treatment are not recommended for use in pregnancy or lactation. The data acquired regarding the safety and efficacy of these therapeutic interventions are gathered from studies or case reports from other diseases, as the treatment modalities are similar and randomized controlled trials are typically not performed in the setting of pregnancy. Although some medications for AIBD treatment are considered unsafe for use in pregnancy, many effective and tolerable therapies are able to provide benefit to these patients. In fact, most first-line agents may be used in pregnancy, to a given extent. This article discusses the medications used to treat AIBD prior to conception, during pregnancy, and while breastfeeding, as well as highlights those that are contraindicated. The preferred approach to management in these patients is also discussed. Additionally, we present the available information regarding neonates of mothers with a diagnosis of AIBD, including the likelihood, identification, and management of neonatal blistering and the effects from medication exposure in utero.

KEY WORDS: Skin diseases; Autoimmune diseases; Pregnancy; Lactation; Therapeutics